Economy

Big Tech's Anthropic and OpenAI stakes are distorting the corporate earnings picture

If you were to strip out Big Tech's investment gains from private AI companies, the earnings story is a lot less bullish.

Trump says oil companies should cut gas prices after making "too much money"

Updated on: August 3, 2026 / 5:12 PM EDT / CBS News

Capital One says it terminated Trump account over money laundering concerns

Capital One Bank said concerns over money laundering were behind the closure of one of President Donald Trump’s bank accounts in 2021, responding to a lawsuit from one of Trump’s financial holding companies.

Stocks making the biggest moves after hours: Palantir, On Semiconductor, Snap & more

These are the stocks posting the largest moves after the bell.

History says this is where the Nasdaq-100 goes next after a correction

CFRA Research found that the tech-heavy index could recover what it lost in just two months, if last week was indeed the bottom.

Twenty five states sue Trump administration over latest global tariffs

Twenty five states sued the Trump administration, arguing its latest global tariffs unlawfully replace duties already struck down by courts.

Here are some of JPMorgan's favorite stocks as August trading kicks off

As August starts, JPMorgan analysts chose their favorite stocks to outperform this month.

SpaceX Set to Release Its First Earnings Report as a Public Company. Here's What to Look For.

Updated on: August 3, 2026 / 2:33 PM EDT / CBS News

Trump says Exxon and Chevron made 'too much money' off high oil prices during Iran conflict: 'I don't like it'

U.S. crude oil prices have gained about 20% since the U.S. and Israel attacked Iran on Feb. 28.

Dividend stocks outperformed the S&P in July. Wall Street says these names will go higher

Investors tend to turn to dividend-payers to help ride out market volatility.

Church & Dwight is an attractive, low beta, consumer staples standout, Katie Stockton says

The baking soda maker's profile can buffer portfolio drawdowns relative to the S&P 500.

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling